Clinical data presented at the european congress on obesity 2022 demonstrates weight loss with gs200 in adults with prediabetes and type 2 diabetes

Boston--(business wire)--gelesis (nyse: gls), a consumer-focused biotherapeutics company and the maker of plenity®, today presented results from the light-up clinical trial for adults with overweight or obesity who have prediabetes or type 2 diabetes and were treated with either gs200 or placebo. approximately 6 out of 10 adults treated with gs200 achieved clinically meaningful response to treatment (achieving at least 5% body weight loss), losing on average 11% of their body weight (~23 pounds
GLS Ratings Summary
GLS Quant Ranking